Skip to main content
SpringerLink
Log in

Prevention of Microvascular Complications of Diabetes – General Overview

  • Chapter
  • First Online:
Principles of Diabetes Mellitus

  • 3968 Accesses

Abstract

Hyperglycemia in both type 1 and type 2 diabetes appears to set off a complex network of intracellular signaling mechanisms that lead to the characteristic microvascular complications of diabetes – retinopathy, nephropathy, and neuropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.

    Article  Google Scholar 

  2. The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.

    Article  Google Scholar 

  3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.

    Article  PubMed  CAS  Google Scholar 

  4. Brownlee M. The pathophysiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625.

    Article  PubMed  CAS  Google Scholar 

  5. He Z. King GL Microvascular complications of diabetes. Endocrinol Metab Clin N Am. 2004;33:215–238.

    Article  CAS  Google Scholar 

  6. Pennathur S Heinecke JW. Oxidative stress and endothelial dysfunction in vascular disease. Curr Diabetes Rep. 2007;7:257–264.

    Article  CAS  Google Scholar 

  7. Schram MT, Chaturvedi N, Schalkwijk C, et al. The EURODIAB prospective complications study group: vascular risk factors and markers of endothelial dysfunction as determinants of inflammatory markers in type 1 diabetes. Diabetes Care. 2003;26:2165–2173.

    Article  PubMed  Google Scholar 

  8. Rask-Madsen C. King GL Mechansims of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3:4656.

    Article  Google Scholar 

  9. Powers AC. Diabetes mellitus. In: Harrison’s Endocrinology. New York, USA: McGraw-Hill; 2006, Ch 17: pp. 299–300.

    Google Scholar 

  10. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 1994;43:1122–1129.

    Article  PubMed  CAS  Google Scholar 

  11. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from hemodynamics to molecular pathology. Eur J Clin Invest. 2004;34:785.

    Article  PubMed  CAS  Google Scholar 

  12. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderate to severe to very severe nonproliferative diabetic retinopathy: initial results of the PK C beta inhibitor DR study multicenter randomized clinical trial. Diabetes. 2005;54:2188–2197.

    Article  Google Scholar 

  13. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaruin on neprhopathy in type 2 diabetes. Diabetes Care. 2005;28:2686–2690.

    Article  PubMed  CAS  Google Scholar 

  14. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341–350.

    Article  PubMed  CAS  Google Scholar 

  15. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy: correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care. 1988;11:34.

    Article  PubMed  CAS  Google Scholar 

  16. Cameron NE, Cotter MA. Effects of protein kinase C beta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev. 2002;18:315.

    Article  PubMed  CAS  Google Scholar 

  17. Monnier L, Mas E, Gine C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. JAMA. 2006;295:1681–1687.

    Article  PubMed  CAS  Google Scholar 

  18. Keenan HA, Costacou T, Sun JK, et al. Clinical factors associated with resistance to microvascular complications of in diabetic patients of extreme disease duration. Diabetes Care. 2007;30:1995–1997.

    Article  PubMed  CAS  Google Scholar 

  19. Thorn LM, Forsblom C, Fagerudd J, et al. Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy. Diabetes Care. 2007;30:1162–1167.

    Article  PubMed  Google Scholar 

  20. The Diabetes Control and Complications Research Group. Clustering of long term complications in families with diabetes in the diabetes control and complciations trial. Diabetes. 1997;46:1829.

    Article  Google Scholar 

  21. Cai H. NAD(P)H oxidase-dependent self propagation of hydrogen peroxide and vascular disease. Circ Res. 2005;96:818–822.

    Article  PubMed  CAS  Google Scholar 

  22. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide formation blocks three pathways of hyperglycemic damage. Nature. 2000;404:787–790.

    Article  PubMed  CAS  Google Scholar 

  23. Brownlee M, Cerami A, Vlassara H. Advanced glycation end products in tissue and the biochemeical basis of diabetic complications. N Engl J Med. 1988;318:1315–1321.

    Article  PubMed  CAS  Google Scholar 

  24. Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 1994;22:11704–11708.

    Article  Google Scholar 

  25. Tanji N. Markowitz GS et al Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nepropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656–1666.

    PubMed  CAS  Google Scholar 

  26. Wang K, Zhou Z. Zhang M et al Peroxisome Proliferator Activator receptor gamma down regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in diabetic and non diabetic rat carotid artery injury model. J Pharmacol Exp Ther. 2006;317:37–43.

    Article  PubMed  CAS  Google Scholar 

  27. Hammes HP, Mariatn S, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 1991;88:11555–11558.

    Article  PubMed  CAS  Google Scholar 

  28. Ellis E, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism. 1991;40:1016–1019.

    Article  PubMed  CAS  Google Scholar 

  29. Li YM, Steffes M. Donnely T et al Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA. 1996;93:3902–3907.

    Article  PubMed  CAS  Google Scholar 

  30. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end products: a review. Diabetologia. 2001;44:129–146.

    Article  PubMed  CAS  Google Scholar 

  31. Clark CM, Lee DA. Prevention and treatment of complications of diabetes mellitus. N Engl J Med. 1995;332:1210–1217.

    Article  PubMed  Google Scholar 

  32. Cameron NE, Eaton SE, Cotter MA. Tesfaye S Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973–1988.

    Article  PubMed  CAS  Google Scholar 

  33. Fioretto P, Steffes MW, Brown DM, Mauer SM. An overview of renal pathology in insulin dependent diabetes mellitus in relation to altered glomerular hemodynamics. Am J Kidney Dis. 1992;20:549–558.

    PubMed  CAS  Google Scholar 

  34. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48–58.

    Article  PubMed  CAS  Google Scholar 

  35. Resnick HE, Bardsley J Foster GL et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002. The national health and nutrition examination survey. Diabetes Care. 2006;29:531–537.

    Article  PubMed  Google Scholar 

  36. Devaraj S, Cheung AT, Jialal I, et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes. 2007;56:2790–2796.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saint Vincent’s Medical Center, New York Medical College, New York, NY, USA

    Vincent Yen

Authors
  1. Vincent Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent Yen .

Editor information

Editors and Affiliations

  1. Div. Endocrinology & Metabolism, Beth Israel Medical Center, East 17th Street 317, New York, 10003, U.S.A.

    Leonid Poretsky

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Yen, V. (2010). Prevention of Microvascular Complications of Diabetes – General Overview. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09841-8_45

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09841-8_45

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09840-1

  • Online ISBN: 978-0-387-09841-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation